MedTrace Logo

Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

NCT02646358 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2016-12-22

No results posted yet for this study

Summary

This is an open-label study designed to evaluate the effect of renal disease on the pharmacokinetics of vepoloxamer relative to the pharmacokinetics in healthy subjects with normal renal function.

Conditions

  • Pharmacokinetics of Vepoloxamer
  • Healthy Volunteers
  • Renal Impaired

Interventions

DRUG

Vepoloxamer

Sponsors & Collaborators

  • Mast Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Edwin L Parsley, DO · Mast Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02646358 on ClinicalTrials.gov